Ardelyx, INC 8-K filings

Ardelyx, Inc. stockholders approved an amendment to its equity incentive plan and elected Class III directors at the 2026 Annual Meeting.

Ardelyx announced robust 2025 financial results, driven by significant IBSRELA revenue growth and progress in its clinical pipeline, while projecting continued expansion into 2026.

Ardelyx announced preliminary unaudited U.S. net product sales of IBSRELA and XPHOZAH, alongside its cash position for Q4 and full-year 2025.

Ardelyx, Inc. announced the resignations of its Chief Legal and Administrative Officer and Chief Medical Officer, both effective December 31, 2025.

Ardelyx, Inc. reported strong third-quarter 2025 financial results, with total product revenue increasing 15% year-over-year, driven by a 92% surge in IBSRELA revenue and a new pipeline program.

Ardelyx, Inc. announced the appointment of Sue Hohenleitner, a former Johnson & Johnson executive, as its new Chief Financial Officer, effective November 4, 2025.

Ardelyx, Inc. reported a 33% year-over-year increase in total revenue for Q2 2025, driven by strong IBSRELA sales, while announcing its CFO's transition and updated corporate bylaws.

Ardelyx, Inc. has entered into a Fifth Amendment to its Loan and Security Agreement, securing an immediate $50 million term loan and an option for an additional $100 million, extending the maturity for new tranches to July 1, 2030.

Ardelyx, Inc. announced that its stockholders approved an amendment to increase the shares available under its equity incentive plan by 10 million, along with the re-election of Class II directors and other key proposals at its 2025 Annual Meeting.

Ardelyx announces a 61% year-over-year increase in total revenue, reaching $74.1 million in Q1 2025, fueled by robust sales of IBSRELA and XPHOZAH.

Ardelyx, Inc. appoints Merdad Parsey, M.D., Ph.D., to its Board of Directors and Nominating and Corporate Governance Committee, effective immediately and June 18, 2025, respectively.

Ardelyx announces significant commercial progress in 2024, with total revenue reaching $333.6 million, driven by strong U.S. net product sales of IBSRELA and XPHOZAH.

Ardelyx announced preliminary unaudited full-year 2024 net product sales of $158 million for IBSRELA and $161 million for XPHOZAH, with a cash balance of approximately $250 million.

Ardelx, Inc. has appointed Joseph Reilly as its new Principal Accounting Officer, effective November 15, 2024, replacing Robert Felsch who will transition to a senior financial advisor role.

Ardelyx announced strong third-quarter 2024 financial results, highlighted by significant revenue growth from both IBSRELA and XPHOZAH, and updated its full-year sales guidance for IBSRELA.

Ardelyx, Inc. has entered into a new lease agreement for a 15,000 square foot facility in Newark, California, while also amending its existing Fremont lease.

Ardelyx has entered into a commercial supply agreement with Catalent for the manufacturing of its IBSRELA product, effective July 23, 2024.

Ardelyx announced strong second-quarter 2024 financial results, highlighted by significant revenue growth from its two commercial products, IBSRELA and XPHOZAH.

Ardelyx has decided not to apply for the Medicare Transitional Drug Add-on Payment Adjustment for XPHOZAH to ensure continued patient access to the drug.

Ardelyx, Inc. announces stockholder approval of amended and restated 2014 Equity Incentive Award Plan and 2014 Employee Stock Purchase Plan at its 2024 Annual Meeting.

Ardelyx, Inc. announces the resignation of its Chief Commercial Officer, Susan Rodriguez, effective May 22, 2024, with an advisory role through the end of the year.

Ardelyx announced a significant increase in first quarter revenue, driven by strong sales of IBSRELA and the successful launch of XPHOZAH, while also reporting a net loss.

Ardelyx, Inc. has obtained a $50 million Term C Loan from SLR Investment Corp. to support its operations and strategic initiatives.

Ardelyx reports a successful 2023 with significant revenue growth driven by strong commercial performance of IBSRELA and the launch of XPHOZAH.